ATL1103 for Cancer and Diabetic Complications Presentation
Released
Released
Announcement PDF
ATL1103 for Cancer and
Diabetic Complications
ASX:ANP
Rationale for ATL1103 for Cancer and Diabetic Complications
ATL1103 is a clinically advanced drug that targets the Growth Hormone receptor (GHr)
Inhibits GHr production in the liver thereby reducing IGF-I in the blood (sIGF-I)
Reducing GH effects and sIGF-I has a potential role in the treatment of a number of
diseases including Acromegaly, Cancer, Diabetic Retinopathy and Nephropathy
Development of ATL1103 for Acromegaly/Endocrinology partnered with Cortendo, however
ANP retains world-wide rights for all other indications (e.g. cancer and diabetic
complications)
Existing ATL1103 toxicology and clinical data would support and expedite future patient trials
in these new indications reducing the time and cost for moving into Phase II
Patents granted to 2024/2025 with potential for up to 5 years extension
Company reviewing the multiple ATL1103 value adding opportunities and expects to report
on plans in the coming months
ATL1103 – Antisense Drug to the Growth Hormone receptor
•
2nd generation antisense inhibitor to the Growth
Hormone receptor (GHr)
•
Inhibits GHr production in the liver which reduces
GH binding to GHr thereby reducing IGF-I
production and secretion
by the liver into the blood
•
IGF-I has a role in the pathogenesis of
acromegaly, diabetic retinopathy, nephropathy
and certain cancers
•
sIGF-I is associated with clinical improvement
in these multiple disease indications
ATL1103 reduces liver GHr &
blocks GH action on the liver
X
GHr
Reducing IGF-I in blood
Adapted from neurosurgery.ucla.edu/body.cfm?id=101
ATL1103 in Cancer
•
Cancer is a disease associated with abnormal cell survival, growth, motility and
adhesion and the insulin-like growth factor (IGF-I) plays an important role1
•
Lower sIGF-I protects against the risk of prostate, breast, lung & colon cancer
Men with prostate cancer in the highest quartile of IGF-I levels had a higher risk than men in
the other quartiles2
o
•
Reduction of sIGF-I using a GHr antagonist decreased tumour volume in breast
cancer in animal models and helped in reducing colon cancer and liver metastasis in
animals3
•
Surgical removal of the pituitary (which reduces GH and sIGF-I) has shown clinical
benefit in the treatment of both prostate and breast cancer patients4
1
2
3
4
Brahmkhatri VP et al, Biomed Res Int 2015
Renehan AT et al Lancet 2004 24; 363 (9418): 1346-53
Waters & Barclay Endocrinology 148, 10: 4533-35 (2007) and
Pearson OH et al Cancer Research 1978, 38, 4323
ATL1103 target (GHr) role in Cancer Prevention
•
Reductions in GH and IGF-I signalling appear to be important in protecting against
development of cancer (Gallagher and LeRoith Cell Metab 13 April 6 2011)
•
GHr deficiency is associated with major reduction in pro-aging signaling, cancer and
diabetes in humans (Guevera-Aguirre, Cohen, et al Sci Transl Med 3. Feb (2011);
Vol3 Issue 70ra 13)
o
99 subjects with Laron syndrome (GHr deficiency) studied over 22 years
-
Subjects experienced only 1 case of cancer (non lethal) vs 17% of the control population
(relatives without the syndrome)
-
No cases of diabetes were observed compared to 5% in the control population
o
Serum from the 99 subjects was tested in vitro and showed decreased cell proliferation potential and
reduced expression of pro-growth signalling and induced higher apoptotic activity, thereby potentially
protecting cells from cancer
o
Authors conclude ‘it is worth considering testing medications that block GH activity in ways that
protect against diseases of ageing, in particular cancer’
ATL1103 for Cancer Treatment (Breast)
•
Breast cancer is the 3rd most prevalent cancer in the developed world
•
Multi Billion dollar sales for drugs currently used to treat breast cancer
•
Breast cancer rates are increased 2-fold in premenopausal women in the high end of the
normal range of sIGF-I1
•
ATL1103 mechanism of action in (breast) cancer treatment is supported and validated by:
o
Data showing ATL1103 reductions in GHr in a human breast cancer cell line, and reductions in GHr
and sIGF-I in mouse, primate and human studies
o
Elevated GHr expression observed in human breast cancer tissues
o
Reduction of sIGF-I using GHr antagonist decreased breast cancer volume in animal models
o
Surgical removal of the pituitary (which reduces sIGF-I and GH) in breast cancer patients who
respond to, or are resistant to tamoxifen (breast cancer treatment), produced remissions of an
average of 11 months2, and in some patients extended life from 5.6 to 25.8 months3
1
2
3
Renehan AG et al Lancet 2004, 363: 1346-1353
Pearson OH et al Cancer Research 1978, 38, 4323
Waters & Barclay Endocrinology 148, 10: 4533-35 (2007)
ATL1103 for Diabetic Retinopathy
•
Diabetic retinopathy (DR) is a disease of the retina caused by diabetes and comes in 2
main forms, non proliferative and the more advanced proliferative form (PDR)
•
In PDR, new blood vessels form and leak blood; oedema and retinal thickening can
also present blocking light reaching the retina thereby potentially causing blindness
•
DR is the leading cause of blindness with ~23,000 cases of blindness per year.
Approx. 300,000 in US and Europe have PDR
•
No approved drugs for advanced PDR – considered a multi billion dollar opportunity
•
ATL1103 mechanism of action in diabetic retinopathy is supported and validated by:
o ANP animal data where an antisense to GHr reduced retinal neo-vascularisation (new blood
vessels) in a mouse model of retinopathy
o Irradiation /ablation of the pituitary gland (which decreases GH and sIGF-I) reduced the number of
blood vessels in the retina of patients and increased their visual acuity
o Somatostatin analogues (that also reduce GH and sIGF-I) such as octreotide provided clinical
benefit in Phase II and III studies
ATL1103 for Diabetic Nephropathy
•
Diabetic nephropathy (DN) is a progressive disease of the kidney glomerulus caused
by high blood sugar
•
About 40% of type II diabetics have DN and 6 million patients in the US, Europe and
Japan have clinically significant forms of the disease
•
Both sIGF-I and local kidney GH/IGF-I have roles in the pathogenesis of DN
•
Despite treatment there is deterioration of renal function and this unmet medical need
is considered a multi-billion dollar opportunity
•
ATL1103 mechanism of action in DN is supported and validated by:
o Data showing ATL1103 reduces GHr and IGF-I in the kidney in primates, and reduces GHr
(GHBP) and sIGF-I in normal volunteer and acromegaly patient studies
o Treatments that reduce GHr and sIGF-I have demonstrated positive effects in mouse models and
have shown benefits in studies in diabetic nephropathy patients
Share your feedback
Discover